Hepion Pharmaceuticals (HEPA) Institutional Ownership $0.06 -0.02 (-29.03%) As of 09:31 AM Eastern Add Compare Share Share Ownership Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Hepion Pharmaceuticals (NASDAQ:HEPA)CurrentInstitutional OwnershipPercentage17.24%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$7.77MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$54.24K Get HEPA Insider Trade Alerts Want to know when executives and insiders are buying or selling Hepion Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data HEPA Institutional Buying and Selling by Quarter Hepion Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/14/2025Anson Funds Management LP105,685$45K0.0%-54.4%0.967% 11/15/2024Anson Funds Management LP231,849$155K0.0%N/A3.331% 8/15/2024Armistice Capital LLC516,000$526K0.0%+32.3%9.428% 2/13/2024Armistice Capital LLC418,000$1.35M0.0%+5.1%9.631% 11/15/2023Armistice Capital LLC397,607$1.98M0.0%N/A10.360% 5/1/2023Virtu Financial LLC53,501$42K0.0%+152.8%0.070% 11/7/2022Virtu Financial LLC67,802$34K0.0%+195.6%0.089% 10/13/2022PVG Asset Management Corp107,915$55K0.2%N/A0.142% 8/12/2022Ikarian Capital LLC410,189$235K0.0%-29.5%0.538% 2/4/2022Envestnet Asset Management Inc.72,027$82K0.0%+87.5%0.094% Get the Latest News and Ratings for HEPA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/2/2022PVG Asset Management Corp100,089$114K0.4%+92.5%0.131% 11/10/2021PVG Asset Management Corp51,989$80K0.2%-72.6%0.068% 11/9/2021BlackRock Inc.1,634,012$2.50M0.0%-1.0%2.144% 11/5/2021PNC Financial Services Group Inc.39,034$60K0.0%N/A0.051% 10/13/2021Asset Management Corp IL ADV133,500$204K0.1%+45.9%0.175% 9/17/2021Virtu Financial LLC113,869$225K0.0%-36.4%0.149% 8/18/2021Ikarian Capital LLC1,365,059$2.70M0.2%N/A1.791% 8/17/2021PVG Asset Management Corp189,616$375K1.2%+1,241.0%0.249% 8/17/2021Boothbay Fund Management LLC155,069$307K0.0%N/A0.203% 8/16/2021Morgan Stanley91,106$180K0.0%+197,956.5%0.120% 8/16/2021State Street Corp322,716$639K0.0%N/A0.423% 8/16/2021Goldman Sachs Group Inc.68,399$135K0.0%N/A0.090% 8/13/2021Altium Capital Management LP446,000$883K0.2%N/A0.585% 8/13/2021Geode Capital Management LLC651,318$1.29M0.0%+10.6%0.854% 8/11/2021BlackRock Inc.1,649,929$3.27M0.0%-3.9%2.165% 8/4/2021Envestnet Asset Management Inc.92,919$184K0.0%+256.9%0.122% 8/2/2021Advisor Group Holdings Inc.17,751$35K0.0%+94.9%0.023% (Data available from 1/1/2016 forward) HEPA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of HEPA shares? During the previous two years, the following institutional investors and hedge funds held shares of Hepion Pharmaceuticals shares: Armistice Capital LLC ($526K), Anson Funds Management LP ($45K).Learn more on Hepion Pharmaceuticals' institutional investors. What percentage of Hepion Pharmaceuticals' stock is owned by institutional investors? 17.24% of Hepion Pharmaceuticals' stock is owned by institutional investors. Learn more on HEPA's institutional investor holdings. Which institutional investors have been buying Hepion Pharmaceuticals' stock? The following institutional investors have purchased Hepion Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($544K), and Anson Funds Management LP ($231.85K). How much institutional buying is happening at Hepion Pharmaceuticals? Institutional investors have bought a total of 231,849 shares in the last 24 months. This purchase volume represents approximately $7.77M in transactions. Which of Hepion Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold Hepion Pharmaceuticals stock in the last 24 months: Anson Funds Management LP ($126.16K). How much institutional selling is happening at Hepion Pharmaceuticals? Institutional investors have sold a total of 126,164 shares in the last 24 months. This volume of shares sold represents approximately $54.24K in transactions. Related Companies ARTL Major Shareholders ENVB Major Shareholders QLGN Major Shareholders GTBP Major Shareholders LIPO Major Shareholders PRFX Major Shareholders VRAX Major Shareholders ATXI Major Shareholders CANF Major Shareholders GLMD Major Shareholders This page (NASDAQ:HEPA) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
